MBMuhammad Ali Butt

Muhammad Ali Butt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammad Ali Butt has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparing the diagnostic performance of 19-gauge and 22-gauge needles in endoscopic ultrasound-guided liver biopsy: a systematic review and meta-analysis

    by Muhammad Ali Butt, Rahul Karna, Sheza Malik, Taimur Sohail Muzammil, Sahla Hammad, Nabeeha Mohy-Ud-Din, Mohammad Bilal

    Liver biopsy is the gold standard for histologic diagnosis of parenchymal liver disease. Endoscopic ultrasound-guided liver biopsy (EUS-LB) is increasingly being performed for tissue acquisition. However, the needle size to perform the procedure is still debated. We performed a systematic review and meta-analysis comparing outcomes and safety of two different needles, 19 gauge (G) and 22 G, for EUS-LB. A comprehensive search of multiple databases was conducted to identify studies comparing 19 G and 22 G needles for liver biopsy. Studies reporting tissue adequacy, histologic diagnosis, and other relevant outcomes were included. A meta-analysis was conducted using random-effects models, and heterogeneity was assessed using standard methods. Our analysis of six studies revealed the superiority of 19 G needles in terms of tissue adequacy (odds ratio [OR] 7.9, 95% confidence interval [CI] 1.9-32.0, P = 0.004) and obtaining a histological diagnosis (OR 7.25, 95% CI 1.4-36.7, P = 0.02) compared to 22 G needles. Both needle sizes performed similarly in obtaining long intact core preprocessing; however, 19 G needles yielded significantly longer intact cores postprocessing. Postprocedural pain was similar between groups. Our meta-analysis supports the preferential use of 19 G needles over 22 G needles for EUS-LB, given their superior performance in tissue adequacy and histological diagnosis with no difference in postprocedural adverse events. These findings underscore the importance of appropriate needle size in optimizing EUS-LB outcomes.


  • Outcomes of peroral endoscopic myotomy in patients with cirrhosis: a multicenter experience

    by Muhammad Ali Butt, Babak Mirminachi, Lizeth Cifuentes, Joo Ha Hwang, Andrew Li, Alexander Schlachterman, Sunil Amin, Shyam Thakkar, Pritesh R. Mutha, Abel Joseph, et al.


  • Association of Hemostatic Blood Product Transfusion With Clinical Outcomes in Esophageal Variceal Bleeding

    by Muhammad A. Butt, Helene Bloom, Sameen Aamer, Adeel Nasrullah, Raza Malik, Carmi S. Punzalan, Shahid M. Malik, Nabeeha Mohy-Ud-Din


  • Tubular adenoma at the hepatico-jejunal anastomosis in familial adenomatous polyposis (FAP) following pancreaticoduodenectomy: challenges in adenoma surveillance and management

    by Muhammad Ali Butt, Lyubov Tiegs, Rahul Karna, Justin Peltola, Mohammad Bilal

    Upper gastrointestinal tumors, including ampullary adenomas, occur frequently in patients with familial adenomatous polyposis (FAP). Guidelines recommend upper gastrointestinal endoscopy in FAP for surveillance of gastric and duodenal adenomas. However, adenomas can rarely arise from biliary epithelium in patients with FAP. Here, we describe a case of tubular adenoma at the hepatico-jejunal anastomosis with intraductal extension in a patient with FAP and previous pancreaticoduodenectomy. This report illustrates a unique case and emphasizes the need for data on postoperative surveillance in patients with FAP, particularly following pancreaticoduodenectomy.

  • The Intersectionality of Race and Gender in Palliative Care Services Utilization Among Critically-Ill Necrotizing Pancreatitis Patients: Analysis of a Large Nationwide Database in the United States

    by Tomas Escobar Gil, Mohammed A Quazi, Amir Humza Sohail, Muhammad Ali Butt, Aman Goyal, Sulaiman Sultan, Farooq Ali Sheikh, Muhammad Salman Khan, Abu Baker Sheikh

    Objective: Necrotizing pancreatitis (NP) is a severe form of pancreatitis that often necessitates intensive care and can result in significant morbidity and mortality. This study aimed to investigate racial and gender disparities in palliative care (PC) utilization among mechanically-ventilated patients with NP. Methods: In this retrospective analysis using the National Inpatient Sample from 2016 to 2020, we investigated 84 335 patients with NP requiring invasive mechanical ventilation, and the utilization of PC services and their disparities based on gender and race. To adjust for potential confounding factors, we employed multivariable logistic regression, ensuring that our findings account for various influencing variables and provide a robust analysis of the data. Results: Among the patients studied, 15.4% utilized PC consultations. Notably, female patients were 12% more likely to utilize PC than their male counterparts (OR 1.1, 95% CI: 1.003-1.2; P = .008). Racial disparities were pronounced: African Americans (OR 0.8, 95% CI 0.7-0.9, P < .001), Hispanic (OR 0.8, 95% CI 0.7-0.9, P = .001), and Asian or Pacific Islander patients (OR 0.74, 95% CI 0.57-0.97; P = .03) had significantly lower odds of utilizing PC compared to White patients. The cohort utilizing PC had a higher in-hospital mortality rate (74.7% vs 24.8%; OR 8.2, 95% CI 7.7-9.2) but a shorter mean hospital stays and lower associated costs. Conclusions: Our findings indicate significant racial and gender disparities in the utilization of PC for intubated patients with NP, with lower utilization among males and minority populations. These findings emphasize the urgent requirement for comprehensive changes in healthcare protocols.


  • Prescription patterns of statins in cirrhotic patients: a survey among primary care physicians and cardiologists

    by Muhammad Ali Butt, Rahul Karna, Shifa Umar, Abhishek Chaturvedi, Srinivas Murali, Tavankit Singh

    Statin therapy is widely utilized for preventing atherosclerotic cardiovascular disease, both as a primary and secondary measure. Despite the American Association for the Study of Liver Diseases’ endorsement of statin use in cirrhotic patients, practitioners exhibit hesitancy, primarily due to concerns regarding hepatotoxicity. This study aimed to evaluate statin prescription patterns in cirrhotic patients by primary care physicians (PCPs) and cardiologists through a survey. A voluntary survey via Survey Monkey with nine objective-type questions was sent to 220 PCPs and 75 cardiologists within Allegheny Health Network. Survey results were collected, and a chi square test was used to compare the two groups. A P value ≤ 0.05 was considered statistically significant. A total of 64 PCPs (29.1%) and 15 cardiologists (20%) completed the survey. Overall, 12.6% did not prescribe statins for primary prevention of atherosclerotic cardiovascular disease in compensated cirrhotic patients. While all cardiologists prescribed statins for secondary prevention, over 50% preferred lower-intensity options. Conversely, 14.1% of PCPs avoided statin prescriptions for secondary prevention. Cardiologists were significantly more inclined to prescribe statins, especially for cirrhosis due to metabolic dysfunction-associated steatotic liver disease compared to PCPs (73.3% vs 45.3%, P = 0.05). Despite increasing evidence favoring use of statins in cirrhosis for improving portal hemodynamics and decreasing ascites, hepatic encephalopathy, the incidence of hepatocellular carcinoma, and mortality, there is still hesitation on the part of prescribers for the fear of worsening liver disease. Wider dissemination of current guidelines and education practices may help to bridge this gap.


  • Inpatient outcomes of inflammatory bowel disease in hospitalized patients with COVID-19: analysis of a nationally representative sample

    by Mohammad Aldiabat, Saqr Alsakarneh, Tyrell Daniel, Muhammad Ali Butt, Balaji Jagdish, James Rock, Aarushi Sudan, Majd Al-Ahmad, Ahmad Jabri, Yassine Kilani, et al.

    To compare the risks of adverse outcomes, including mortality, gastrointestinal bleeding, and venous thromboembolism, between COVID-19 patients with inflammatory bowel disease (IBD) and those without IBD. We analyzed data from the National Inpatient Sample between January and December 2020. The study included adult patients with Crohn's disease (CD) and ulcerative colitis (UC) who contracted COVID-19. Inpatient outcomes were compared between the IBD and non-IBD COVID-19 cohorts. Out of 1,050,045 COVID-19 hospitalizations, 0.28% had CD (2954 patients) and 0.26% had UC (2794 patients). After adjusting for confounding factors, UC patients had a significantly higher risk of deep vein thrombosis compared to non-IBD patients, with an adjusted odds ratio (aOR) of 2.55 (P < 0.001). However, CD patients did not show a significant association with deep vein thrombosis (aOR 1.29, P = 0.329). There were no significant associations between IBD patients (both UC and CD) and pulmonary embolism, nonvariceal gastrointestinal bleeding, or in-hospital mortality. UC patients had a longer average hospital stay (8.25 days) compared to non-IBD patients (adjusted mean difference 0.89, P = 0.007). Healthcare resource utilization was similar among the three groups. Our national study on COVID-19 hospitalizations indicates that patients with IBD have comparable rates of gastrointestinal bleeding, pulmonary embolism, and mortality as those without IBD. However, patients with UC hospitalized with COVID-19 have a higher risk of deep vein thrombosis than COVID-19 patients hospitalized without UC. Further research is needed to better understand the relationship between COVID-19 and IBD.


  • Henoch-Schonlein Purpura, an Unusual Presentation of Acute Myeloid Leukemia

    by Muhammad Ali Butt, Sameen Aamer, Anastasios Kapetanos

    Background/Aim: Acute myeloid leukemia (AML) is a hematologic malignancy that accounts for most annual deaths from leukemias in the United States. Although rare, cutaneous manifestations may be the first clinical sign of AML. Henoch Schonlein Purpura (HSP), as a manifestation of AML, has an unknown incidence. Here, we present a case of HSP as the presenting manifestation of AML. Case Report: A 58-year-old woman presented to the Emergency Department with a rash and itching of all her extremities. The rash began on her thighs and arms a month prior and gradually spread distally. On presentation, she appeared alert and was hemodynamically stable. Skin examination revealed palpable purpura and plaques, with petechiae involving all extremities. Admission labs revealed a hemoglobin and hematocrit of 8 g/dl and 24% respectively. The white blood cell count was 1.23 k/mcl, absolute neutrophil count was 0.31 k/mcl, and platelets were 172,000 k/mcl. A broad work-up was carried out. Subsequently, skin and bone marrow biopsies were performed. Skin biopsy was positive for vascular immune reactivity with IgA, consistent with HSP. The bone marrow biopsy revealed hypocellular marrow with atypical blast infiltrates constituting 10-15% of cellularity, indicating AML. The patient was transferred to malignant hematology service where and started on induction chemotherapy for AML. Conclusion: Prompt diagnosis and treatment of AML is crucial for better clinical outcomes. Our case suggests that HSP can be a rare presenting manifestation of AML. It is important to consider hematologic malignancy in patients presenting with HSP in the right clinical context as part of differential diagnosis.

  • July effect in clinical outcomes of esophagogastroduodenoscopy performed at teaching hospitals in the United States

    by Karthik Gangu, Sanket Basida, Rehmat Ullah Awan, Mohammad Ali Butt, Austin Reed, Rao Afzal, Rahul Shekhar, Harleen Kaur Chela, Ebubekir S. Daglilar, Abu Baker Sheikh

    Esophagogastroduodenoscopy (EGD) is a common procedure used for both diagnosis and treatment, but carries risks such as bleeding and perforation. The “July effect”—described as increased complication rates during the transition of new trainees—has been studied in other procedures, but has not been thoroughly evaluated for EGD. We used the National Inpatient Sample database for 2016 to 2018 to compare outcomes in EGD performed between July to September and April to June. Approximately 0.91 million patients in the study received EGD between July to September (49.35%) and April to June (50.65%), with no significant differences between the two groups in terms of age, gender, race, income, or insurance status. Of the 911,235 patients, 19,280 died during the study period following EGD, 2.14% (July–September) vs 1.95% (April–June), with an adjusted odds ratio of 1.09 (P < 0.01). The adjusted total hospitalization charge was $2052 higher in July–September ($81,597) vs April to June ($79,023) (P < 0.005). The mean length of stay was 6.8 days (July–September) vs 6.6 days (April–June) (P < 0.001). The results of this study are reassuring as the July effect on inpatient outcomes for EGDs was not significantly different according to our study. We recommend seeking prompt treatment and improving new trainee training and interspecialty communication for better patient outcomes.


  • Open Access

    Acute Respiratory Distress Syndrome and the Use of Inhaled Pulmonary Vasodilators in the COVID-19 Era: A Narrative Review

    by Adeel Nasrullah, Shiza Virk, Aaisha Shah, Max Jacobs, Amina Hamza, Abu Baker Sheikh, Anam Javed, Muhammad Ali Butt, Swathi Sangli

    The Coronavirus disease (COVID-19) pandemic of 2019 has resulted in significant morbidity and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of September 2022, more than 6.5 million patients have died globally, and up to 5% required intensive care unit treatment. COVID-19-associated ARDS (CARDS) differs from the typical ARDS due to distinct pathology involving the pulmonary vasculature endothelium, resulting in diffuse thrombi in the pulmonary circulation and impaired gas exchange. The National Institute of Health and the Society of Critical Care Medicine recommend lung-protective ventilation, prone ventilation, and neuromuscular blockade as needed. Further, a trial of pulmonary vasodilators is suggested for those who develop refractory hypoxemia. A review of the prior literature on inhaled pulmonary vasodilators in ARDS suggests only a transient improvement in oxygenation, with no mortality benefit. This narrative review aims to highlight the fundamental principles in ARDS management, delineate the fundamental differences between CARDS and ARDS, and describe the comprehensive use of inhaled pulmonary vasodilators. In addition, with the differing pathophysiology of CARDS from the typical ARDS, we sought to evaluate the current evidence regarding the use of inhaled pulmonary vasodilators in CARDS.